The most common site of distant metastasis is the lung.

Distant metastases are also common, even if the primary tumor is controlled.

The final group includes patients with distant metastases (M1) that were found at the time of diagnosis.

Approximately 50% of patients with recurrent disease experience distant metastasis.

About 30% of tumors are malignant and have local or distant metastases.

After surgery, many patients develop regional or distant metastases.

Prognosis is related to tumor size and the presence of distant metastases.

The prognosis for patients with distant metastases is poor.

Radiation therapy may be used to palliate central disease or distant metastases.

Many patients treated surgically subsequently develop regional or distant metastases.

Distant metastasis: The cancer has spread to distant parts of the body.

Treatment of distant metastases is usually not curative but may produce significant palliation.

Patients with distant metastases have a poor prognosis and can be appropriately offered treatment on a clinical trial.

When there is distant metastasis, the cancer is generally considered incurable.

Of these individuals about 40% present with metastatic disease and a further third will develop distant metastases during the postoperative course.

Patients with distant metastases (M1) are always considered to have ED.

Local invasion of surrounding tissues or distant metastases indicate malignancy.

M describes distant metastasis (spread of cancer from one part of the body to another).

Distant metastases are treated with hormonal therapy, chemotherapy, or a combination of both.

Distant metastasis other than to nonregional lymph nodes and lung.

Treatment for men with distant metastases (cancer that has spread to other parts of the body) may be hormone therapy, chemotherapy, or both.

Distant metastases of melanoma typically are found in the skin, liver, lungs, bone, and brain.

No clinical or radiographic evidence of distant metastases.

Men with positive lymph nodes or distant metastases at the time of diagnosis were excluded from the analysis.

Inactivation of nm23 may therefore prove a useful guide to the risk of distant metastasis.